Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
202 Results for "
Osteosarcoma
" in MedChemExpress (MCE) Product Catalog:
Products (202)
202 Results for "Osteosarcoma" in MCE Product Catalog:
Cat. No.: HY-183980
Target:
Research Areas:
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research .
Target:
Research Areas:
JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
Cat. No.: HY-171656
CAS No.: 946378-12-7
Target:
Glycosidase NF-κB COX STAT ERK p38 MAPK Apoptosis CDK Survivin Bcl-2 Family
Research Areas:
G721-0282 is an orally active CHI3L1 inhibitor. G721-0282 can reduce the expression of inflammatory proteins and cytokines. G721-0282 inhibits the activation of the NF-κB signaling pathway. G721-0282 inhibits neuroinflammation and reduces anxious behavior. G721-0282 significantly inhibits the proliferation of osteosarcoma (OS) cells by suppressing the STAT3 signaling pathway. G721-0282 induces OS cell apoptosis by upregulating pro-apoptotic protein levels and downregulating anti-apoptotic protein levels. G721-0282 can be used for researches on neuroinflammatory conditions and cancer .
Cat. No.: HY-17509S
CAS No.: 2012598-48-8
Synonyms: SC 046-d3; SC 46-d3; SC 59046-d3
Cat. No.: HY-182539
CAS No.: 1202877-06-2
Target:
Research Areas:
Cat. No.: HY-N1408
CAS No.: 22255-22-7
Synonyms: trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene
Cat. No.: HY-P990208
Target:
Research Areas:
Cat. No.: HY-W703540
CAS No.: 1794780-24-7
Synonyms: SC 046-d4; SC 46-d4; SC 59046-d4
Cat. No.: HY-12238R
CAS No.: 1127442-82-3
Synonyms: endo-IWR 1 (Standard); IWR-1-endo (Standard)
Target:
Research Areas:
IWR-1 (Standard) is the analytical standard of IWR-1 (HY-12238). This product is intended for research and analytical applications. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
Cat. No.: HY-19876
CAS No.: 935481-06-4
Synonyms: Debio-0827
Research Areas:
PL37 (Debio-0827) is an orally active, blood-brain barrier permeable dual enkephalinase inhibitor. PL37 inhibits aminopeptidase N, neprilysin, and metalloproteases, thereby blocking the degradation of endogenous enkephalins, elevating enkephalin levels, and activating peripheral μ- and δ-opioid receptors. PL37 induces mitochondrial dysfunction, mitophagy, and apoptosis, inhibits endothelial cell proliferation, migration, invasion, and tube formation, and suppresses hemangioma tumor growth and angiogenesis. PL37 can be used in research related to peripheral neuropathic pain, osteosarcoma-induced hyperalgesia, painful diabetic neuropathy, migraine, bone cancer pain, neuroinflammatory pain, and infantile hemangioma .
Cat. No.: HY-N3387
CAS No.: 30508-27-1
Cat. No.: HY-159756
Target:
Research Areas:
KI-MS2-008b is the enantiomer of KI-MS2-008 (HY-159756B). KI-MS2-008 is a selective Max binder. KI-MS2-008 exhibits anticancer activity against Myc-dependent cancers .
Cat. No.: HY-165740
CAS No.: 65988-71-8
Synonyms: Disialoganglioside GD2
Ganglioside GD2 (Disialoganglioside GD2) is a tumor-associated antigen. Ganglioside GD2 shows limited expression in normal tissues but is overexpressed in multiple tumor types, and thus can serve as a target in cancer. Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action relies on enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on the tumor type .
Cat. No.: HY-12238G
CAS No.: 1127442-82-3
Synonyms: endo-IWR 1 (GMP); IWR-1-endo (GMP)
Cat. No.: HY-187521
CAS No.: 102537-38-2
Target:
Research Areas:
MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a Kd of 4 μM for MYC and an IC50 of 10 μM for topoisomerase IIα (Topoisomerase IIα). MYCMI-7 hydrobromide binds directly to MYC, selectively inhibits the interactions of MYC:MAX and MYCN:MAX, reduces MYC-driven transcription levels, induces MYC/MYCN protein degradation, and blocks the binding of MYC to chromatin, thereby inducing tumor cell growth arrest, apoptosis and reducing cell viability, while only inducing G1 phase growth arrest in normal cells. MYCMI-7 hydrobromide can be used in research related to MYC-driven acute myeloid leukemia and breast cancer, MYCN-amplified neuroblastoma, glioblastoma, Burkitt's lymphoma, melanoma, colon cancer, osteosarcoma, cervical cancer and histiocytic lymphoma .
Cat. No.: HY-N17440
CAS No.: 15127-94-3
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb
Target:
Research Areas:
VU 0364439 is a mGlu4 positive allosteric modulator with an EC50 of 19.8 nM. VU 0364439 modulates the GRM4/CBX4/HIF-1α signaling pathway by enhancing GRM4-CBX4 interaction. VU 0364439 can be used for the research of parkinson’s disease .
Cat. No.: HY-181933
CAS No.: 339025-18-2
Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC50 of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC50 of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC50 of 29.7 μM .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
